Paper
1
Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma
Authors
Keith Sullivan,Ellen Goldmuntz
L. Keyes-Elstein,Peter McSweeney,Ashley Pinckney,Beverly Welch,Maureen Mayes,Richard Nash,Leslie Crofford,Barry Eggleston,Sharon Castina,Linda Griffith,Julia Goldstein,D. Wallace,Oana Crăciunescu,Dinesh Khanna,Rodney Folz,Jonathan Goldin,E. Clair,James Seibold,Kristine Phillips,Shin Mineishi,Robert Simms,Karen Ballen,Mark Wener,George Georges,Shelly Heimfeld,Chitra Hosing,Stephen Forman,Suzanne Kafaja,Richard Silver,Leroy Griffing,Jan Storek,Sharon LeClercq,Richard Brasington,Mary Csuka,Chris Bredeson,Carolyn Keever-Taylor,Robyn Domsic,M. Kahaleh,T. Medsger,Daniel Fürst,Lynette Keyes-Elstein,David Wallace,Oana Craciunescu,Christopher Bredeson,Thomas Medsger
+45 authors
,Daniel FurstPublished
Jan 4, 2018
Show more
Save
Tip1
TipSave
Abstract
Despite current therapies, diffuse cutaneous systemic sclerosis (scleroderma) often has a devastating outcome. We compared myeloablative CD34+ selected autologous hematopoietic stem-cell transplantation with immunosuppression by means of 12 monthly infusions of cyclophosphamide in patients with scleroderma.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.